Margaret Cruickshank

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

Kimberley Kavanagh, Kevin G. Pollock, Kate Cuschieri et al. · The Lancet Infectious Diseases · 2017 · 258 citations · Full text

Vaccination, Cervical Health, Human Papillomavirus Vaccines +7

Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study

Timothy Palmer, Lynn Wallace, Kevin Pollock et al. · BMJ · 2019 · 235 citations · Full text

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M. Wheeler, S. Rachel Skinner, Maria Rowena Del Rosario‐Raymundo et al. · The Lancet Infectious Diseases · 2016 · 187 citations

Vaccination, Vaccine Safety, Vaccinology +12

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

S. Rachel Skinner, Anne Szarewski, Barbara Romanowski et al. · The Lancet · 2014 · 180 citations

Vaccination, Vaccine Safety, Vaccinology +13

Profiling Cytochrome <i>P</i>450 Expression in Ovarian Cancer: Identification of Prognostic Markers

Diane L. Downie, Morag McFadyen, Patrick H. Rooney et al. · Clinical Cancer Research · 2005 · 164 citations